Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis

Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis

Abstract Background The maintenance dosage of selexipag is categorized as low, medium or high. In order to assess the efficacy and safety of different dosages of selexipag for the risk stratification of pulmonary arterial hypertension (PAH), we performed a systematic review and meta‐analysis. Method...

Full description

Bibliographic Details
Main Authors:	Shang Wang, Yi Yan, Jian Zhang, Ping Yuan, Ci‐Jun Luo, Hong‐Ling Qiu, Hui‐Ting Li, Jian Xu, Lan Wang, Tian‐Lan Li, Rong Jiang
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Series:	Animal Models and Experimental Medicine
Subjects:	individualized treatments meta‐analysis prostacyclin receptor agonist risk stratification systematic review
Online Access:	https://doi.org/10.1002/ame2.12347

Similar Items

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
by: Hardin EA, et al.
Published: (2016-11-01)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
by: Mizuki Momoi, et al.
Published: (2022-01-01)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
by: Elizabeth Colglazier, et al.
Published: (2022-10-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-08-01)

Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension
by: Kazuya Kuramoto, et al.
Published: (2023-04-01)

Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies
by: Frances Varian, et al.
Published: (2024-01-01)

Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts
by: Maurizio Cutolo, et al.
Published: (2018-05-01)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
by: Mariangela Lattanzio, et al.
Published: (2022-10-01)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
by: Colin Hinkamp, et al.
Published: (2022-10-01)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
by: Akram Khan, et al.
Published: (2023-01-01)

Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study
by: Yuen Tsang, et al.
Published: (2023-12-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
by: Stephanie S. Handler, et al.
Published: (2022-07-01)

Pulmonary hypertension
by: LP Nicod
Published: (2003-02-01)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
by: Pengwei Wang, et al.
Published: (2022-02-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
by: Şükran Yıldırım
Published: (2023-07-01)

Pathways in pulmonary arterial hypertension: the future is here
by: Olivier Sitbon, et al.
Published: (2012-12-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)

Inhaled Iloprost as a First-Line Therapy for Persistent Pulmonary Hypertension of the Newborn
by: Seung Hyun Kim, et al.
Published: (2019-11-01)

Medical management of pulmonary arterial hypertension in pregnancy: A single center experience
by: Lauren Lastinger, et al.
Published: (2021-08-01)

Inhaled iloprost induces long‐term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy
by: Kenichiro Yasuda, et al.
Published: (2022-04-01)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
by: Rebecca R. Vanderpool, et al.
Published: (2022-05-01)

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
by: Justin J. Kochanski, et al.
Published: (2024-01-01)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
by: Agnieszka Blitek, et al.
Published: (2022-08-01)

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series
by: Elizabeth Colglazier, et al.
Published: (2023-07-01)

Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
by: Ryohei Suzuki, et al.
Published: (2022-08-01)

Selexipag in pregnancy and pulmonary arterial hypertension
by: Sweta Mohanty, et al.
Published: (2023-01-01)

Case report: Extracorporeal life support as a successful bridge to recovery in an incident case of pulmonary arterial hypertension
by: Benjamin Pequignot, et al.
Published: (2024-02-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
by: Abdullah A. Alqarni, et al.
Published: (2023-08-01)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-02-01)

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
by: M. Delcroix, et al.
Published: (2009-12-01)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
by: Vijay P. Balasubramanian, et al.
Published: (2022-01-01)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
by: Raj Parikh, et al.
Published: (2022-10-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01)

Selexipag in the management of pulmonary arterial hypertension: an update
by: Coghlan JG, et al.
Published: (2019-08-01)

Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study
by: Raquel Paulinetti Camara, et al.
Published: (2023-03-01)

Effect of Prostanoids on Human Platelet Function: An Overview
by: Steffen Braune, et al.
Published: (2020-11-01)

Effects of Leukoreduction and Storage on Erythrocyte Phosphatidylserine Expression and Eicosanoid Concentrations in Units of Canine Packed Red Blood Cells
by: S.M. Muro, et al.
Published: (2017-03-01)